Skip to content

Comparative study of therapeutic effects of Gabapentin versus plasebo on Restless legs syndrome in hemodialysis patientes

Comparative study of therapeutic effects of Gabapentin versus plasebo on Restless legs syndrome in hemodialysis patientes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014092319273N1
Enrollment
109
Registered
2015-08-12
Start date
2014-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RLS: Restless Legs syndrome. Other specified extrapyramidal and movement disorders

Interventions

Intervention 1: capsules of gabapentin 100mg after every hemodialysis for 4 weeks axir pharmaceutical co. Intervention 2: capsule plasebo after every hemodialysis for 4 weeks. the cartridge similar to
Treatment - Drugs
Placebo
capsules of gabapentin 100mg after every hemodialysis for 4 weeks axir pharmaceutical co.
capsule plasebo after every hemodialysis for 4 weeks. the cartridge similar to real capsule was filled with starch powder

Sponsors

Vice-chancellor of Research and Technology of Ahvaz,Jundishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion critria: at least 3 months of hemodialysis ;international severity scale more than 8 Exclusion criteria: Pregnancy ;Under treatment with psychotropic agents ;presence of another neurologic disease ;Iron deficiency anemia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of restless leg syndrome. Timepoint: At first and 4 weeks after first drug administration and4 weeks after second drug administration. Method of measurement: with international scale.

Secondary

MeasureTime frame
Drug advers reaction. Timepoint: At first and 4 weeks after first drug administration and 4 weeks after second drug administration. Method of measurement: with question from patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza alizadeh attar

Ahvaz,Jundishapur University of Medical Sciences

sanysasan2002@yahoo.com+98 613552837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026